Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation

Treatment of ALK-rearranged non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKIs) is challenged by the almost inevitable emergence of therapeutic resistance. Different profiles of resistance mechanisms have been reported for the currently available ALK TKIs. The ALK C1156Y mutati...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, Chuangzhou, Nie, Liangqin, Wu, Xiaokang, Miao, Xiaobo, Chen, Ting, Chen, Liuxi, Zhang, Dongqing, Lin, Quan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530790/
https://www.ncbi.nlm.nih.gov/pubmed/36203454
http://dx.doi.org/10.3389/fonc.2022.915502

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530790/
https://www.ncbi.nlm.nih.gov/pubmed/36203454
http://dx.doi.org/10.3389/fonc.2022.915502

Ejemplares similares